Trade Landos Biopharma, Inc. - LABP CFD

Trading Conditions

• Spread: 0.26
• Long position overnight feeLong position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position-0.026179 %(-US$1.05)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: -0.026179%
• Short position overnight feeShort position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position0.003957 %(US$0.16)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: 0.003957%
• Overnight fee time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 20
• Stock exchange: United States of America
• Commission on trade: 0%

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: -0.026179 %
  (-US$1.05)

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: 0.003957 %
  (US$0.16)

Key Stats

• Prev. Close: 22.15
• Open: 22.11
• 1-Year Change: 5718.42%
• Day's Range: 22.1 - 22.36

Landos Biopharma, Inc. Company profile

About Landos Biopharma Inc

Landos Biopharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. The Company through its artificial intelligence (AI)-based precision medicine platform, LANCE platform, identifies therapeutic targets based on predictions of immunometabolic function and create therapeutic candidates to engage those targets in areas of unmet medical need. Its platform discovers small molecule therapeutics for patients with autoimmune diseases that targets mechanisms of action, including LANCL2, NLRX1 and PLXDC2 immunometabolic pathways. It identifies novel immunometabolic targets and product candidates across indications, such as ulcerative colitis (UC), Crohn’s disease (CD), eosinophilic esophagitis (EoE), systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its Omilancor is an oral, gut restricted LANCL2 agonist in development for the treatment of UC, CD and EoE.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Landos Biopharma Inc revenues increased from $0K to $18M. Net loss decreased 3% to $18.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.48 to -$0.57.